Oncology Institute, Inc. (TOI)
NASDAQ:TOI
US Market
Holding TOI?
Track your performance easily

Oncology Institute, Inc. (TOI) Stock Forecast & Price Target

44 Followers
See the Price Targets and Ratings of:

TOI Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Oncology
Institute, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TOI Stock 12 Month Forecast

There Are No Analyst Ratings for TOI In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

TOI Financial Forecast

TOI Earnings Forecast

The previous quarter’s earnings for TOI were -$0.17.
The previous quarter’s earnings for TOI were -$0.17.

TOI Sales Forecast

Next quarter’s sales forecast for TOI is $107.54M with a range of $107.54M to $107.54M. The previous quarter’s sales results were $98.58M. TOI beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.95% of the time in the same period. In the last calendar year TOI has Outperformed its overall industry.
Next quarter’s sales forecast for TOI is $107.54M with a range of $107.54M to $107.54M. The previous quarter’s sales results were $98.58M. TOI beat its sales estimates 50.00% of the time in past 12 months, while its overall industry beat sales estimates 46.95% of the time in the same period. In the last calendar year TOI has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$2
Buy
582.59%
Upside
Reiterated
06/10/24
We hosted Dr. 2024 JEF HC Conference. Key takes include: 1) The VBC pipeline remains robust with more wins expected this year, 2) interest in VBC Specialty remains high from plans & at-risk entities accelerating TOI's sales cycle, 3) bridging from 1Q EBITDA to the FY24 guide requires growth & margin improvement (both Rx & VBC related), and 4) mgmt's focus remains on cash conservation & turning the corner to profitability. VBC Geographies & Pulling Through.

Best Analysts Covering Oncology Institute, Inc.

Which Analyst Should I Follow If I Want to Buy TOI and Sell After:
1 Month
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
-3.60%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -3.60% per trade.
3 Months
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-54.40%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -54.40% per trade.
1 Year
Jack SlevinJefferies
Success Rate
0/2 ratings generated profit
0%
Average Return
-59.60%
reiterated a buy rating 5 months ago
Copying Jack Slevin's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.60% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-59.60%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -59.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TOI Analyst Recommendation Trends

Rating
Mar 23
Jun 23
Sep 23
Feb 24
Jun 24
Strong Buy
1
2
2
2
2
Buy
2
1
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
3
3
3
3
In the current month, TOI has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TOI average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

TOI Stock Forecast FAQ

What is TOI’s average 12-month price target, according to analysts?
Currently, no data Available
What is TOI’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TOI, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is TOI a Buy, Sell or Hold?
      Currently, no data Available
      What is Oncology Institute, Inc.’s price target?
      Currently, no data Available
      What do analysts say about Oncology Institute, Inc.?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of TOI?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis